Bristol-Myers Squibb (BMY) shares rebound after recent losses. Analysts weigh in on its value, growth potential, and updated ...

Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...